
Lilly experimental ‘triple g’ obesity drug leads to 24.2% weight loss in trial -NEJM
June 26 (Reuters) – Eli Lilly (LLY.N) on Monday said a mid-stage trial of its next-generation obesity drug candidate “triple G” showed that it led to weight loss of up to 24.2% after 48 weeks, surpassing results seen with other weight loss drugs.The once-weekly injected drug, retatrutide, is part of a class known as incretins… […]